biotech · Unresectable or metastatic conventional chondrosarcoma · Advanced or metastatic solid tumors · INBX
Inhibrx Biosciences
Inhibrx Biosciences clinical programs — 5 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2010
- Employees
- 114
- Programs
- 10
- Drugs
- 17
- Patents
- 35
Inhibrx Biosciences projects
5 ClinicalTrials.gov programs sponsored by Inhibrx Biosciences.
Inhibrx Biosciences has 5 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
INBRX-106 - Hexavalent OX40 agonist antibody
Inhibrx Biosciences
Solid Tumor
1 trial -
INBRX-109
Inhibrx Biosciences
Conventional Chondrosarcoma
1 trial -
Pembrolizumab
Inhibrx Biosciences
Triple Negative Breast Cancer
1 trial -
Ph1 INBRX-109 Part 3
Inhibrx Biosciences
Advanced or metastatic solid tumors
1 trial -
Ph2 INBRX-109 SA CS
Inhibrx Biosciences
Unresectable or metastatic conventional chondrosarcoma
1 trial
Frequently asked questions
How many clinical projects does Inhibrx Biosciences have?
5 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.